Life Sciences partner Sophie McGrath and associate Kesten Laverty explain that women’s health and wellness industry has expanded exponentially over the last few years. Read the Maddyness UK article here.
Related Content
- Life Sciences PerspectivesJune 28, 2024
The USPTO Proposes a Radical Change to Terminal Disclaimer Practice: You Have an Opportunity to Comment
- Big Molecule WatchJune 28, 2024
Biogen’s TOFIDENCE (tocilizumab) Approved in the EU
- Life Sciences PerspectivesJune 27, 2024
FDA Issues Overdue Draft Guidance on Clinical Trial Diversity Action Plans
- InsightJune 27, 2024
FDA Issues Overdue Draft Guidance on Clinical Trial Diversity Action Plans
- Alert27 June 2024
UK General Election: Key Employment-Related Manifesto Pledges
- Big Molecule WatchJune 26, 2024
Eculizumab BPCIA Litigation Update: Court Denies Alexion’s Motion for an Injunction Pending Appeal
- Big Molecule WatchJune 25, 2024
Now Available! Announcing the Vaccine Patent Litigation and Vaccine Patent PTAB Trackers
- Big Molecule WatchJune 21, 2024
Update on John Hopkins and Merck Pembrolizumab Litigation
- Speaking EngagementsJuly 24, 2024 | 2:00 PM - 3:15 PM ET
ACS Webinar - Avoiding IP Own Goals in Drug Discovery: Best Practices for Obtaining (and Keeping) Your IP
- Press Release1 July 2024
Amid Ongoing Regional Growth, Goodwin Relocates Singapore Office
- Press ReleaseJune 28, 2024
Entrada Therapeutics Closes $100 Million Registered Direct Offering
- WebinarJune 27, 2024
The Future of Non-Compete Agreements in America
- Press ReleaseJune 26, 2024
UroMems raises €44 million in Series C Financing
- Press ReleaseJune 18, 2024
Marea Therapeutics Launches with $190 Million Series A and Series B Financings
- WebinarJune 13, 2024 | 1:00 PM - 2:00 PM EDT
Antitrust Implications of State Regulators’ Increasing Scrutiny
- Awards and RankingsJune 13, 2024
The Legal 500 US 2024 Recognizes 44 Goodwin Practices and 187 Lawyers